WHAT IS CLAIMED IS:

1. A solid oral dosage form comprising

(I) a delayed release component comprising:

(a) a core comprising from about 5 mg to about 40 mg of doxylamine and/or a pharmaceutically acceptable salt thereof and from about 5 mg to about 40 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof;

(b) an enteric coating surrounding said core; and

(II) an immediate release component comprising:

(c) a first active ingredient-containing immediate release coating surrounding said enteric coating and comprising (i) from about 5 mg to about 40 mg of doxylamine and/or a pharmaceutically acceptable salt thereof, or (ii) from about 5 mg to about 40 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof; and

(d) a second active ingredient-containing immediate release coating surrounding said first active ingredient-containing coating and comprising (i) about 5 mg to about 40 mg of doxylamine and/or a pharmaceutically acceptable salt thereof, or (ii) from about 5 mg to about 40 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof;

wherein if said first active ingredient-containing immediate release coating comprises said doxylamine and/or pharmaceutically acceptable salt thereof, said second active ingredient-containing immediate release coating comprises said pyridoxine and/or pharmaceutically acceptable salt thereof, and if said first active ingredient-containing immediate release coating comprises said pyridoxine and/or pharmaceutically acceptable salt thereof, said second active ingredient-containing immediate release coating comprises said doxylamine and/or pharmaceutically acceptable salt thereof.

2. The solid oral dosage form of claim 1, wherein said core comprises about 10 mg of said doxylamine or pharmaceutically acceptable salt thereof.

3. The solid oral dosage form of claim 1 or 2, wherein said core comprises doxylamine succinate.

4. The solid oral dosage form of any one of claims 1 to 3, wherein said core comprises about 10 mg of said pyridoxine or pharmaceutically acceptable salt thereof.

5. The solid oral dosage form of any one of claims 1 to 4, wherein said core comprises pyridoxine hydrochloride.

6. The solid oral dosage form of any one of claims 1 to 5, wherein said first or second active ingredient-containing immediate release coating comprises about 10 mg of said doxylamine or pharmaceutically acceptable salt thereof.

7. The solid oral dosage form of any one of claims 1 to 6, wherein said first or second active ingredient-containing immediate release coating comprises doxylamine succinate.

8. The solid oral dosage form of any one of claims 1 to 7, wherein said first or second active ingredient-containing immediate release coating comprises about 10 mg of said pyridoxine or pharmaceutically acceptable salt thereof.

9. The solid oral dosage form of any one of claims 1 to 8, wherein said first or second active ingredient-containing immediate release coating comprises pyridoxine hydrochloride.

10. The solid oral dosage form of any one of claims 1 to 9, wherein said first and/or second active ingredient-containing immediate release coating comprises an immediate release film coating system.

11. The solid oral dosage form of any one of claims 1 to 10, wherein said core is present in an amount of about 50% to about 70% (w/w) of said solid oral dosage form.

12. The solid oral dosage form of any one of claims 1 to 11, wherein said enteric coating is present in an amount of about 2% to about 15% (w/w) of said solid oral dosage form.

13. The solid oral dosage form of any one of claims 1 to 12, wherein said enteric coating comprises an acrylic polymer or co-polymer.

14. The solid oral dosage form of claim 13, wherein said acrylic polymer or co-polymer is a copolymer based on methacrylic acid and ethyl acrylate.

15. The solid oral dosage form of any one of claims 1 to 14, wherein said first active ingredient-containing immediate release coating is present in an amount of about 4% to about 12% (w/w) in said solid oral dosage form.

16. The solid oral dosage form of any one of claims 1 to 15, further comprising a first intermediate coating surrounding said first active ingredient-containing immediate release coating.

17. The solid oral dosage form of claim 16, wherein said first intermediate coating is present in an amount of about 1% to about 4% (w/w) in said solid oral dosage form.

18. The solid oral dosage form of claim 16 or 17, wherein said first intermediate coating comprises a film coating system.

19. The solid oral dosage form of any one of claims 1 to 18, wherein said second active ingredient-containing immediate release coating is present in an amount of about 5% to about 15% (w/w) of said solid oral dosage form.

20. The solid oral dosage form of any one of claims 1 to 19, further comprising a second intermediate coating between said core and said enteric coating.

21. The solid oral dosage form of any one of claims 1 to 20, further comprising a third intermediate coating between said enteric coating and said first active ingredient-containing immediate release coating.

22. The solid oral dosage form of any one of claims 1 to 21, further comprising a seal coating surrounding said second active ingredient-containing immediate release coating.

23. The solid oral dosage form of claim 22, wherein said seal coating is present in an amount of about 2% to about 10% (w/w) of said solid oral dosage form.

24. The solid oral dosage form of claim 22 or 23, wherein said seal coating comprises a film coating system.

25. The solid oral dosage form of any one of claims 22 to 24, further comprising a solid oral dosage form-coating agent surrounding said seal coating.

26. The solid oral dosage form of claim 25, wherein said solid oral dosage form-coating agent is present in an amount of about 0.005% to about 0.5% (w/w) of said solid oral dosage form.

27. The solid oral dosage form of claim 25 or 26, wherein said solid oral dosage form-coating agent comprises wax.

28. The solid oral dosage form of any one of claims 1 to 27, wherein said solid oral dosage form is a tablet.

29. A solid oral dosage form comprising:

(I) a delayed release component comprising:

(a) a core comprising about 10 mg of doxylamine succinate and about 10 mg of pyridoxine hydrochloride;

(b) a second intermediate coating surrounding said core;

(c) an enteric coating surrounding said second intermediate coating; and

(d) a third intermediate coating surrounding said enteric coating; and

(II) an immediate release component comprising:

(e) a first active ingredient-containing immediate release coating surrounding said third intermediate coating and comprising about 10 mg of pyridoxine hydrochloride;

(f) a first intermediate coating surrounding said first active ingredient-containing immediate release coating;

(g) a second active ingredient-containing immediate release coating surrounding said first intermediate coating and comprising about 10 mg of doxylamine succinate;

(h) a seal coating surrounding said second active ingredient-containing immediate release coating; and

(i) a solid oral dosage form-coating agent surrounding said seal coating.

30. The solid oral dosage form of any one of claims 1 to 29, for use in alleviating the symptoms of nausea and vomiting of human pregnancy.

31. The solid oral dosage form of any one of claims 1 to 29, for use in the manufacture of a medicament for alleviating the symptoms of nausea and vomiting of human pregnancy.

32. Use of the solid oral dosage form of any one of claims 1 to 29, for alleviating the symptoms of nausea and vomiting of human pregnancy.

33. Use of the solid oral dosage form of any one of claims 1 to 29, for the manufacture of a medicament for alleviating the symptoms of nausea and vomiting of human pregnancy.